BioWorld

April 8, 2005

View Archived Issues

Genelabs' Prestara Again In Trouble, This Time In Taiwan

The path to market for Genelabs Technologies Inc.'s lupus drug Prestara narrowed this week when another Phase III trial failed to meet the primary endpoint. (BioWorld Today) Read More

BioMarin Pushes Phenoptin Into Pivotal Program In PKU

Read More

A David Vs. Goliath Biotech Story, With Goliath Winning

Read More

Avanir Raises $17M, Continues Work On Neurodex Rolling NDA

Read More

Other News To Note

Read More